JAZZ Q4 2023 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena

JAZZJazz Pharmaceuticals plc

$12B

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.0B+4.1% YoY

Gross Profit

$905M89.4% margin

Operating Income

$122M12.1% margin

Net Income

$94M9.3% margin

EPS (Diluted)

$1.42

QoQ Revenue Growth

+4.1%

Cash Flow

Operating Cash Flow

$167M

Free Cash Flow

$139M

Stock-Based Comp.

$53M

Balance Sheet

Total Assets

$11.4B

Total Liabilities

$7.7B

Stockholders' Equity

$3.7B

Cash & Equivalents

$1.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$972M	+4.1%
Gross Profit	$905M	$805M	+12.4%
Operating Income	$122M	-$263M	+146.5%
Net Income	$94M	-$240M	+139.2%